Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has accepted its Biologics License Application submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF and APRIL cytokines, in adults with immunoglobulin A nephropathy. The FDA has assigned a PDUFA target action date of November 30, 2026. If povetacicept is approved by the FDA, Vertex plans to launch povetacicept in a low-volume.
The submission is supported by positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept in IgAN.
In pre-market trading on NasdaqGS, Vertex shares are down 0.24 percent to $446.45.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.